Online study of genetic risk in people with Parkinson's disease
Offers genetic testing for GBA1 and LRRK2 gene changes in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: PD Frontline (Part of RAPSODI GD) Remote Assessment of People With Parkinson's
Key facts
- Where
- London, United KingdomSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Source: NCT06151002, who can take part
Where in United Kingdom
- University College London (UCL)London, United KingdomTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University College, London
- Trial code
- NCT06151002
- Record updated
- 29 October 2026
- Original description
PD Frontline (part of RAPSODI GD) is an online study observational study for People with Parkinson's. The aims are to better understand the genetic nature of Parkinson's and to connect participants to clinical trials and studies, particularly those with a genetic focus.Read full original descriptionShow less
PD Frontline, Part of RAPSODI GD (Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher's Disease) to Build an Online Trial-ready Cohort of GBA Genotyped People With Parkinson's
PD Frontline (part of RAPSODI GD) is an online study observational study for People with Parkinson's. The aims are to better understand the genetic nature of Parkinson's and to connect participants to clinical trials and studies, particularly those with a genetic focus.
To do this, participants are offered genetic sequencing for two common genetic risk factors for Parkinson's Disease, the GBA1 and LRRK2 gene, with an at-home sample collection kit. Return postage is free.
Inclusion: Formal diagnosis of Parkinson Disease.
Exclusion: History of Parkinsonism (progressive supranuclear palsy, multiple system atrophy, traumatic, manganese toxicity, postencephalitic, vascular PD; drug induced PD; corticobasal degeneration); Individuals with another neurological disorder including: dementia, movement disorders, and motor neurone disease; Individuals on drugs known to be associated with parkinsonism, including neuroleptic agents (Amisulpride, Chlorpromazine Hydrochloride, Flupenthixol, Fluphenazine Hydrochloride, Haloperidol, Methotrimeprazine, Levomepromazine, Olanzapine, Oxypertine, Pericyazine, Perphenazine, Pimozide, Pipotiazine, Prochlorperazine, Promazine Hydrochloride, Reserpine, Risperidone, Sulpiride, Thioridazine, Trifluoperazine, Zuclopenthixol acetate, Zotepine), plus Bupropion, , Lithium, Methyldopa, Metoclopramide and Sodium Valproate); Confirmation that the individual carries a GBA1 variant (GBA positive). These individuals will be referred to sister-study, RAPSODI.